Pharmacological inhibition of the ACE/Ang-2/AT1 axis alleviates mechanical ventilation-induced pulmonary fibrosis
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.111855 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Jinhua Feng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China. Hauptthemen laut MEDLINE: Pulmonary Fibrosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Science and Technology Development Foundation.
Themen: Beatmung und Weaning
Abstract (Originalsprache)
Mechanical ventilation (MV) is an essential therapy for acute respiratory distress syndrome (ARDS) and pulmonary fibrosis. However, it can also induce mechanical ventilation-induced pulmonary fibrosis (MVPF) and the underlying mechanism remains unknown. Based on a mouse model of MVPF, the present study aimed to explore the role of the angiotensin-converting enzyme/angiotensin II/angiotensin type 1 receptor (ACE/Ang-2/AT1R) axis in the process of MVPF. In addition, recombinant angiotensin-converting enzyme 2(rACE2), AT1R inhibitor valsartan, AGTR1-directed shRNA and ACE inhibitor perindopril were applied to verify the effect of inhibiting ACE/Ang-2/AT1R axis in the treatment of MVPF. Our study found MV induced an inflammatory reaction and collagen deposition in mouse lung tissue accompanied by the activation of ACE in lung tissue, increased concentration of Ang-2 in bronchoalveolar lavage fluid (BALF), and upregulation of AT1R in alveolar epithelial cells. The process of pulmonary fibrosis could be alleviated by the application of the ACE inhibitor perindopril, ATIR inhibitor valsartan and AGTR1-directed shRNA. Meanwhile, rACE2 could also alleviate MVPF through the degradation of Ang-2. Our finding indicated the ACE/Ang-2/AT1R axis played an essential role in the pathogenesis of MVPF. Pharmacological inhibition of the ACE/Ang-2/AT1R axis might be a promising strategy for the treatment of MVPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
- Department of Critical Care Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China. Electronic address: msy0413@126.com.
- Department of Critical Care Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China. Electronic address: zhengyuheshsmu@163.com.
Förderung
- National Natural Science Foundation of China
- Shanghai Science and Technology Development Foundation
Zitieren
APA
Feng, J., Huang, X., Xu, Q., Tang, R., Zhou, Y., Qin, S., Xing, S., Gao, Y., Mei, S., & He, Z. (2024). Pharmacological inhibition of the ACE/Ang-2/AT1 axis alleviates mechanical ventilation-induced pulmonary fibrosis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.111855
Vancouver
Feng J, Huang X, Xu Q, Tang R, Zhou Y, Qin S, et al. Pharmacological inhibition of the ACE/Ang-2/AT1 axis alleviates mechanical ventilation-induced pulmonary fibrosis. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.111855
BibTeX
@article{Feng2024,
author = {Feng, Jinhua and Huang, Xi and Xu, Qiaoyi and Tang, Ri and Zhou, Yang and Qin, Shaojie and Xing, Shunpeng and Gao, Yuan and Mei, Shuya and He, Zhengyu},
title = {Pharmacological inhibition of the ACE/Ang-2/AT1 axis alleviates mechanical ventilation-induced pulmonary fibrosis},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.111855}
}
EUVIMED